Histopathologic and molecular characterization of BAP‐1‐inactivated melanoma. (23rd November 2022)

• Record Type: Journal Article
• Authors: Miller, Elisabeth M.; Linos, Konstantinos; Bacchi, Carlos E.; Gru, Alejandro A.; Raghavan, Shyam S.
• Is Part Of: Journal of cutaneous pathology. Volume 50:Number 4(2023)
• Page Start: 349
• Page End: 357
• Publication Date: 2022-11-23
• Subjects: BAP‐1 -- melanoma -- molecular; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616
• DOI: 10.1111/cup.14346
• Languages: English
• ISSNs: 0303-6987

Abstract

Abstract: Background: BRCA1‐associated protein 1 (BAP‐1) is a deubiquitylase that functions as a tumor suppressor, regulating multiple cellular processes including cell cycle control, differentiation, cell death, and DNA repair. BAP‐1‐inactivated melanocytic tumors (BIMTs) have recently been described and are characterized by epithelioid cytomorphology, are often clonal in appearance, and typically do not recur or show malignant transformation on follow‐up. Aim: To describe the histopathologic and molecular characterization of five cases of BAP‐1‐inactivated cutaneous malignant melanomas. Methods: The archives at two separate institutions were retrospectively searched for tumors classified as melanoma with loss of BAP‐1 via immunohistochemistry. Five cases were identified. These cases were classified as malignant melanoma based on cytomorphology, immunohistochemistry, and ancillary molecular testing. The clinical demographics were recorded, along with the histomorphologic features of each case. Genomic analysis for all cases was performed via OncoScan. Results: The five reviewed cases consisted of two females and three males ranging from 67 to 74 years in age. Molecular characterization of each case was performed using OncoScan. Microarray assay showed that there was a complete deletion of 3p in all cases, BRAF V600E mutation in two cases, NRAS missense variant in one case, and loss of 9p in three cases. All cases showed malignant copy number alterations. Conclusions: Herein we describe five cases of BAP‐1‐inactivated melanomas confirmed by histomorphology and immunohistochemistry, all of which show malignant copy number profiles including loss of 3p. In addition, we provide a case of a likely BIMT showing progression to BAP‐1‐inactivated melanoma on a 16‐year follow‐up.